- Business Wire•15 hours agoARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer
ARIAD Pharmaceuticals, Inc. , a rare cancer-focused innovative biotechnology company, today announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase inhibitor, from the ongoing Phase 1/2 and pivotal ALTA trials in patients with ALK-positive non-small cell lung cancer and intracranial central nervous system metastases.
- Business Wire•3 days agoARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer
ARIAD Pharmaceuticals, Inc. , a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the clinical data presented on brigatinib, the Company’s investigational anaplastic lymphoma kinase inhibitor, at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer .
ARIA : Summary for ARIAD Pharmaceuticals, Inc. - Yahoo Finance
ARIAD Pharmaceuticals, Inc. (ARIA)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||13.26 x 3000|
|Ask||13.39 x 7500|
|Day's Range||13.10 - 13.46|
|52 Week Range||4.37 - 14.42|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-76.32|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|